肺癌表观遗传学治疗的研究进展  

Research progress of epigenetics therapy for lung cancer

作　　者：栾加强 杜振宗[1] 

机构地区：[1]桂林医学院附属医院,广西省桂林市541000

出　　处：《中国肿瘤临床》2013年第24期1570-1572,共3页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金项目(编号:81160296)资助~~

摘　　要：肺癌是目前发病率和死亡率较高的恶性肿瘤之一,其5年生存率不到15%。研究表明肺癌的发生是多种因素造成的,表观遗传是重要因素之一。近年来,随着甲基化转移酶抑制剂及组蛋白去乙酰化酶抑制剂等表观治疗药物在临床的成功应用,以及它们具有增加肿瘤化疗敏感程度的作用,表观遗传成为近来研究的热点。本文就表观遗传学中DNA甲基化、乙酰化及肿瘤化疗敏感性在肺癌诊断及治疗等方面的研究进展作综述。The five-year survival rate of lung cancer, one of the cancers with higher morbidity and death rate, is less than 15%. Studies have shown that the occurrence of lung cancer is related to many factors in which epigenetics is an important one. In recent years, with the successful clinical application of epigenetic therapy drugs such as methylation transferase and histone deacetylase inhibi-tors that can enhance the sensitivity of chemotherapy, epigenetics has become a research hotspot. This paper briefly introduces the re-search progress in DNA methylation, acetylation, and cancer chemotherapy sensitivity in lung cancer diagnosis and treatment.

关 键 词：肺癌 表观遗传学 DNA甲基化 组蛋白修饰 治疗 

分 类 号：R734.2[医药卫生—肿瘤]